Multiple Sclerosis Market Size, Share, Growth Analysis, By Drug type(Immunomodulators, and Immunosuppressant), By Route of Administration(Injectables, Oral, and Others), By Diagnosis(Magnetic Resonance Imaging (MRI) Scans, Simple Electrical Stimulation Tests, and Lumbar Puncture), By Region - Industry Forecast 2024-2031

As the Asia Pacific region's healthcare sector grows rapidly, there will be an increased demand for healthcare experts. China and India are expected to dominate the multiple sclerosis treatment markets due to their large populations and high prevalence of the condition. China, India, and Malaysia will all make significant contributions to the Southeast Asian market's growth rate. Multiple sclerosis diagnoses are predicted to rise in Asian countries, particularly in the Asia Pacific area, as the demand for health care services grows. Asia-Pacific is predicted to expand the quickest over the projection period.

Multiple sclerosis treatment is the world's second-largest market, thanks to Europe's expanding healthcare industry and healthcare coverage. Germany and France are leading the market growth for multiple sclerosis treatment in Europe. With its enormous pharmaceutical business, Germany is predicted to experience the fastest growth during the assessment period. Several markets dominate the multiple sclerosis market, with Europe coming in second behind Asia Pacific. The North American multiple sclerosis treatment market is expected to reach USD 14.76 billion at a CAGR of 6.76% by 2030, owing to rapid development of the medical sector in the United States and an increase in the number of research institutions for better disease treatment. The United States dominates the market. Multiple sclerosis is also driven by increased healthcare penetration in the United States and Canada, which results in a greater number of procedures.